






Lynne Wilkinson 18.11.2017

### HIV Self-Screening

# Mpumalanga SAHCS




University of the Witwatersrand

WITS RHI

## **Outline**

- Understanding the testing gap
- What is HIV self-screening?
- Evidence to date
- WHO Guidance
- HIVSS products & WHO prequalification
- Oraquick and how it works
- Why HIV self-screening for SA?
- South African Guidelines
- Roll out in SA:
- Q&A






# Understanding the HIV testing gap

# HIV diagnosis over time

Average % of PLHIV Identified for Top 30 Countries\*, Yearly, Starting 2001







Projection suggests the earliest countries could identify 90% of PLHIV is 2026.

# South Africa towards the 90/90/90 goals


#### South Africa: HIV treatment cascade



Percentage of people living with HIV who know their HIV status



Percentage of people living with HIV who are on antiretroviral treatment




HIV who are virally suppressed

Source: Towards 90-90-90 Dec 2016



#### Unequal progress towards UNAIDS 90-90-90 targets





What is HIV self-screening?



# What IS HIV self-screening?


Collects

**Performs** 

Interprets






















 A process in which a person collects his or her own specimen (oral fluid or blood) and then performs an HIV test and interprets the result, often in a private setting, either alone or with someone he or she trusts

HIVST is a "screening test" or Test for Triage






### What HIVSS IS NOT

• It is **not here to replace other HTS modalities** from which the majority of the population learn their status.

• It is **not** a **definitive test**, but rather the first step towards learning a status. All POSITIVE results must be confirmed using the national algorithm.





# **Evidence on HIVSS**


### **Evidence on HIVSS**

- 5 RCTs (2012-2016) directly comparing HIVST to HIV testing by a provider as of July 2016
- 25 studies on HIV RDT for self-testing performance as of April 2016
- 125 studies on acceptability/feasibility (including user values preferences) as of July 2016
  - 4 studies on cost/cost-effectiveness as of July 2016




# HIVSS Doubled Uptake & Frequency compared to standard HTS

Moderate quality evidence that HIVST doubled HIV testing uptake compared to standard HTS




Low quality evidence that HIVST resulted in 2 more tests in a 12-15 month period compared to standard HTS



Effect also shown for increase uptake of couples testing in Gichangi et al & Thirumurthy et al.

Jamil et al also showed HIVST increased the frequency of testing among non-recent testers compared to standard HTS

# HIVSS identified 2x's as many HIV-infections than only standard HTS




# Across observational studies - HIV positivity ranged from

3–14% among the general population in sub-Saharan Africa

1–30% among key populations Africa, America, Asia, Europe

### Median HIV positivity Studies in African region



# No identifiable increased risk of social harm & adverse events


- Studies reported HIVST was empowering.
- Social harm due to HIVST was not identified in RCTs
- Reports from studies were limited and did not suggest HIVST increased risk of harm
- In Malawi, two-years of implementing HIVST found no suicides, no self-harm and no cases of IPV.
  - Reports of coercion identified were mostly among men who also reported that they would recommend HIVST
- In Kenya 4 cases of IPV identified unclear if due to HIVST. (41% of participants reported IPV 12 months prior to intervention).






# Results of HIV RDTs performed by self-tester were similar to those performed by trained health worker

Measured using kappa statistic – 16 studies




# Achieved acceptable accuracy (sensitivity & specificity)



# **Acceptability & Willingness**


Generally good uptake (median 76%, range 24-100%)

22 studies



Generally high acceptability & willingness (median 73%, range 21-100%)

84 studies



# Linkage to care

50-56% in general populations in sub-Saharan Africa and 20-100% among key populations Africa, Americas, Asia, Europe

Effect also shown for increase uptake of couples testing in Choko et al & Thirumurthy et al.





#### **HIVSS Values & Preferences in Africa**


- HIVST is highly acceptable across different populations & settings, e.g. men, young people, KP, couples
- Many users prefer oral HIVST— but others, e.g. men in South Africa and PWID reported a preference for fingerprick HIVST.
- Preferences across service delivery approaches vary.
  - Young people preferred community-based options, but key populations, reported preferences for pharmacies, the Internet, and over-the-counter approaches more appealing because they are more discreet and private














# WHO Normative Guidance on HIV Self-Testing

# WHO HIVST Strategy



- HIVST requires self-testers with a reactive (positive) result to receive further testing from a trained provider using a validated national testing algorithm.
  - All self-testers with a nonreactive test result should retest if they might have been exposed to HIV in the preceding six weeks, or are at high ongoing HIV risk.
- HIVST is **not** recommended for people taking anti-retroviral drugs, as this may cause a false non-reactive result.

#### **Directly assisted HIV self-testing**



- Trained peer or health worker could provide a brief demonstration on how to use the kit and how to interpret results
- Provide face-to-face assistance during self-testing (optional)
- Instruction-for-use &/or included in the kit:

#### **Unassisted HIV self-testing**

#### Instruction-for-use included in the kit:

- Pictorial/written
- Including a hotline number or a link to a video
- Remote support via SMS, QR code or mobile messaging applications
- Package inserts included in the kit



# HIVST Service Delivery Approaches



Pharmacy-based

Communitybased (door-to-door)

Internet-based





Workplace programmes

PrEP programmes



Partner-delivered

**Facility-based** 

(pick-up/self-test


on site)

Integrated (e.g. VMMC, TB, STIs, reproductive health)









# HIVSS products & WHO prequalification



### What is WHO Pre-Qualification?

- Prequalification is an assessment made by WHO regarding the quality, safety, performance and suitability of an IVD/MD when it is used in WHO Member States
- WHO prequalification is a risk-based procedure founded on best regulatory practice
- WHO undertakes a comprehensive assessment of individual IVDs/MDs through a standardized procedure aimed at determining if the product meets PQ requirements.

# Why WHO Pre-Qualification?

- The PQ decision is used by UN bodies and procurement agencies as a means for quality assuring IVDs/MD and other health products
- The PQ decision can be used by Member States without strong regulatory systems or with limited resources to provide assurance of quality, safety and performance
- The PQ decision is used by health implementing programmes to guide product selection

### First WHO PQ device

 27 July 2017, OraQuick was granted pre-qualification after meeting all of the requirements of the WHO assessment process

 Currently, 3 products that are in the WHO PQ review pipeline, and we should have at least 1 blood-based PQ product by Q2 2018







# OraQuick HIV self-screen

# **OraQuick HIV Self-Screening Kit**

#### The kit includes:

- Instructions
- Bottle stand
- Bottle with testing liquid
- Testing pad







## OraQuick HIV Self-Screening Kit


- Requires a swab of the gums → pain free!
- Takes 20-40 minutes
- Easy to read results

A positive result does not mean that a person is infected with HIV, they need to have additional testing with their health care provider.

If a person was exposed to HIV less than 3 months ago, they need to screen again to be sure that their status is truly negative.



### How to self-screen



# Negative

Inconclusive

Inconclusive







1

2

3

### Inconclusive

# Positive

### Inconclusive









4

5

6

## What to do with a positive screen?

- Client needs to go to a health facility or community testing to have a rapid diagnostic test performed by a Health care provider
- If that test is positive, the health care provider will perform an additional confirmatory rapid test
- If that test is positive the client will be linked to care at the health facility for ART initiation



# What to do with a negative screen?

- If the client has been exposed to HIV in the last 3 months they will need to rescreen 3 months after exposure
- If the client has not been exposed to HIV in the last 3 months the client can consider themselves HIVnegative
- The client should be educated and linked to care for HIV combination prevention including VMMC and PrEP services





# What is an inconclusive screen and what to do?

(Also: indeterminate, invalid, and unsure of result)

 If the client has an inconclusive screen they need to go to a health facility or community testing for repeat screening by a health care provider



### **HIVSS** is not recommended for:

 Any client on ARVs or PREP – may give false negative result

Has not been validated for use in children
 412 years

Limited userability assessment <15 years</li>

### Client Questions and Answers

How does it work?
The kit looks for HIV antibodies in the oral fluids you collect from your gums.

## How well does it work?

The oral HIV selfscreening kit is more than 90% accurate.

### Do I have to share my result?

No. It is confidential. You can choose who you share your results with. BUT if you do have a positive result this doesn't mean you definitely have HIV, you need to have a confirmatory test with a health care provider.

# How long does the test take?

It is fast! Only 20-40 minutes.

### Does it hurt?

Not at all! It is a pain free swab of your gums.

Can the kit detect
other diseases?
No, It only detects HIV.
If you need to be
tested for pregnancy or
for an STI you need to
go see a health
provider.



# Why am I testing oral fluids, can HIV be spread through saliva?

HIV is not in saliva or oral fluids, but the antibodies your body makes to fight HIV can be detected there. This makes the kit a good option for people who don't like their blood drawn.


I'm on PrEP, can I use the self-screening kit?
No, anyone using ARVs, for either treatment or prevention, should not use a self-screening kit as it can give you a false negative result.

I'm worried I have been exposed to HIV within the past 72 hours, can I still use the HIV self-screening kit?

No, you should not use the kit, you should visit your health care provider as soon as possible to access Post Exposure Prophylaxis (PEP).


I'm on ARVs, can I use the self-screening kit?

No, HIV self-screening kits are not suitable for those who are on ARVs as they may give a false negative result.





# WHY HIV self-screening for SA



Source: Towards 90-90-90 Dec 2016











## **NOW WE HAVE:** a WHO PQ device



### SA regulation of medical devices:

SAPRHA constituted 2 June 2017



### The difference...



### INSTI HIV SELF TEST INSTRUCTIONS

Questions? 4+1-604-204-6784

### INSIDE YOUR TEST KIT











BOTTLE 1

BOTTLE 2

BOTTLE 3

TEST DEVICE POUCH

### PREPARATION









2. Place the test device down on a flat surface.



3. Remove cap of Bottle 1. Place on flat surface.

### STEP 1: COLLECT BLOOD



1. Twist off tip. Throw away tip in waste bin.



2. Rub finger until warm.



3. Place lancet on the side of finger tip.



4. Rub finger to get larger round drop of blood.



Let 1 drop fall into Bottle 1.



6. Twist on cap of Bottle 1.

- 3. Hold the end of the empty pipette to the blood droplet, gently squeezing the bulb at the end. Release the pressure on the bulb to draw blood into the pipette and fill the stem of the pipette with blood. Avoid drawing air bubbles into the pipette.
- 4. When doing the test, the blood in the pipette must be transferred into the cassette sample well as quickly as possible to avoid clotting in the pipette. Hold the pipette in a vertical position and immediately dispense 2 free-falling drops of the blood sample into the centre of the sample well.
- 5. Cut the end of the sealed pipette with diluent open and add 1 drop of the
- diluent into the same sample well. 6. After 2 minutes, if the colour has not moved across the test window or if blood is stil present in the sample well, add 1 or 2 drops of the diluent to the sample well.
- It is important that the background is clear before the result is read. Wait for the coloured lines to appear. Read results in 15 minutes. Do not interpret.
- the result after 15 minutes When testing with serum instead of whole blood, 1 drop of serum and one drop.

of reagent should be used.









INTERPRETATION OF RESULTS

Negative
One colour line is visible in the Control (C) region.
This result indicates that at present in the sample tested there are no HIV-1 and HIV-2. antibodies or that the concentration of HIV antibodies is below the detection limit of test. A negative result at any time does not preclude the possibility of an HIV infection

Two colour lines are visible, one in the Control (C) region and one in the Test (T) region If the Tline is light coloured, this should be considered as a possible positive result ar be followed up with a laboratory test.

A positive test result indicates the presence of antibodies to HIV in the sample. Any positive results should be followed up with a laboratory test.

If there are no visible colour lines, the result is invalid.

Proper procedures may not have been followed in performing the assay, or the t may have deteriorated.

The sample should be re-tested with a new test.

ALL POSITIVE TESTS MUST BE FOLLOWED UP BY A VISIT TO A HEALTHCARE PRACTITIONE FOR CONFIRMATION. TO BE USED IN CONJUNCTION WITH PRE AND POST COUNSELL KEEP OUT OF REACH OF CHILDREN

For OTC and professional in vitro diagnostic use only. Do not use after the expira date. Do not eat, drink or smoke in the area where the specimens or kits are hand Do not use test if pouch is damaged. Handle all specimens as if they co infectious agents. Observe established precautions against microbiological ha throughout the procedure and follow the standard procedures for proper disporspecimens. Humidity and temperature can adversely affect results.

### STORAGE INSTRUCTIONS

Store at room temperature or refrigerated (15 °C - 30 °C). Keep from direct moisture and heat. Do not freeze the test.

### RODUCED FOR

ew Clicks South Africa (Pty) Ltd nr. of Searle and Pontac Streets. ape Town, 8001 outh Africa : 021 4601626




A long and healthy life for all South Africans





# SA guidance

# South African policy on HIV self-screening






HIV self-testing (HIVST) is a process in which an individual who wants to know his or her HIV status collects a specimen, performs a test and interprets the result by him or herself, often in private. Prepared by the national C HIVST is a pre-screening test and does not provide a definitive diagnosis. It does not replace the need for the screening and confirmatory HIV test in the validated national testing algorithm. A reactive self-test result must always be followed by additional testing conducted by a trained provider who operates according to the validated national diagnostic testing algorithm.


> A k HIVST provides people an opportunity to test discretely and conveniently and may increase uptake of HIV testing among people not reached by other HIV services. HIVST is currently under policy consideration in South Africa.

Clients participating in clinical vaccine trials should be referred back to their research site for appropriate testing to avoid misdiagnosis.

### Translating Policy into Practice – Enabling Environment for HIVST in South Africa



National HIVSS guidelines will be published in Nov 2017, through a multi-stakeholder consultative process and in alignment with broader national HTS priorities



### Guideline:

### DRAFT NATIONAL HIV SELF SCREENING

S



Private Bag X828, PRETORIA, 0001. 27th Floor, Room 2710, Civitas, Cnr Thabo Sehume & Struben Street, PRETORIA, 0001 Tel: +27 (0) 12 395 8000, Fax: +27 (0) 12 395 8422

Enquiries: Dr Thato Chidarikire, Telephone: (012) 395 9153, Email: Thato.Chidarikire@health.gov.za

Dr S Mohangi Head of Department Mpumalanga Health Private Bag X11285 NELSPRUIT 1200

REQUEST SUPPORT FOR IMPLEMENTATION OF THE STAR PHASE 2 PROJECT FOR HIV SELF SCREENING IN MPUMALANGA

Dear Dr Mohangi



To be finalized mid November 2017

### **HIV SELF-SCREENING:**

### What it is and how to integrate it into HIV Testing Services

The National Department of Hoalth and the South African Pharmacy Gouncil supports the use of MiniC approved HM self-screening liftship progid who may not be utility to access. Society-based testing for different reasons. HM self-screening provides an approximity for such people to screen themsolven in private and in their own time.

HIV self-screening is not intended to displace facility-based HIV testing but is rather a complementary approach to reach previously untested, hard-to-reach, and test-averse populations.

Currently, the MHO approved GraQuick and HM self-screening RH. In approved for the South African market. The Ora-Quick and HM self-screening kit detects HM antibodies in out fluids collected from a sunrounds.



Any positive result from a self-screening kit requires confirmatory testing using the national HIV testing algorithm.

Display algorithm NOW including HIV self-screening.

HW'self-screening refers to a process in which a person-collects his or her own specimen-joral fluid or blood; and then perkerns an HW limit and interprets the exact, siter in a pervate setting, either alone or with someone he or she trusts.

All healthcare providers should support clients who have self-screened by conducting a rapid HIV screening test and if positive, a confirmatory rapid HIV test together with appropriate pre- and post-test counselling.

A reactive (positive) result always requires confirmatory testing by a trained tester following the rotional testing alworthm.

Interpretation of a non-reactive (inegative) result will depend on the ongoing itsi of INV opposize. Industriats with possible opposize within the past 3 months should be encouraged to re-screen 3 months after passible INV opposize. While individuals with high ongoing risk, should be encouraged to re-screen regularly. Re-screening can be done with an INV self-test or a lacitity-formed rapid test.

A person may also get an invalid result or may have struggled to interpret their result. Instructions in the list reconment attending a health facility, where a trained tester will conduct testing following the national testing algorithm.

HV self-scroning is not recommended for anyone on ARNs or REP, as It may lead to a labor negative result. It has also not been validated for any person under the age of 12 years.

HV self-covering is acceptable to many people accountificant contests and can therefore increase uptake and thequency of HIV feeling, particularly among populations at high ongoing risk of HV, who may be less likely to access testing or test less linquerity than recommended.

HV nilf-scroning kits used by self-testors can perform as accurately as when used by a trained testor.


### Birkensone .

Californ on W. off, bring and pater will alian upplement in annothined gainformed Wireley areas. Mold built Ogustatus W.S. Satural Wireley areas policy look Max Natural Apartment of leaks W.S.



A long and healthy life for all South Africans







Home based

Clinic based

### CLIENT PERFORMS HIV SELF-SCREEN AT HOME



Reactive (Positive) Result

Client needs to seek confirmatory testing Non Reactive (Negative) Result


Client advised:


- To retest if HIV exposure in past 3 months or less, and
- To seek linkage to relevant HIV prevention services



### **HIV Combination Prevention**

- Condoms
- PrEP
- Counseling
- PEP
- · Healthy Lifestyles
- · Treatment for STIs
- MMC
- · ART for partners living with HIV





# Also important in SA HIVSS guidelines:

Do not use if on ARVs or PREP

Do not use <12 years old</li>

 If 12-17 years ensure demonstration provided and post HIVSS support available



### Referral Card



### Dear Sister in charge

This client has screened for HIV using an HIV self-screen and may have received a reactive (positive) result. Please ensure that the client is provided with confirmatory testing and appropriate counselling in terms of the national HIV testing algorithm.

This requires a rapid HIV screening test and if positive, a further rapid confirmatory test. Where the client is confirmed HIV positive, please ensure the client is prepared and scheduled for ART initiation as per national guidelines.

Please also reflect that the client HIV self-screened in the new column in your HIV testing register (if not at your clinic yet - please indicate "HIVSS" next to the client's name).

Should you have any questions, please contact:

YARRA





## Implementation South Africa



### **HIV Self-Testing Africa: The STAR Initiative**










### Introduction to the STAR Initiative

- Multiple sites, models, and populations
- Normalizing HIV self-screening in Southern Africa
- Providing evidence for scale-up
- Encouraging policy change
- Enabling the regulatory environment
- Reducing barriers

Phase 1 (2015 – 2017)	Phase II (2017 – 2020)
Zimbabwe, Zambia, Malawi	Zimbabwe, Zambia, Malawi + South Africa, Swaziland, Lesotho

# Number of HIV Self-Screen kits distributed by channel (2015-2017)



681,791
HIV selfscreen kits
distributed
as of Aug
2017


# 3 Objectives in SA

- 1. Enabling environment
- Pilot, implement and learn from HIVST distribution models
  - 3. Facilitating transition into and scale-up within national system (costed plan/supply/national and donor budgets/M&E etc)




## WITS RHI Year 1 distribution

models




### Workplace distribution models







## **Community distribution models**



## **Community distribution models**



# Facility distribution models







### Acknowledgements

- WHO HIV Dept: Cheryl Johnson and Rachel Baggaley
- Mohammed Majam & Wits RHI Colleagues
- SA HIV Clinicians Society and the Guidelines TWG
- Funders: BMGF, Aids Fonds & UNITAID
- STAR II Consortium Partners PSI, CHAI and SFH

LYNNE WILKINSON – Snr Programme Manager STAR Wits RHI <a href="mailto:lwilkinson@wrhi.ac.za">lwilkinson@wrhi.ac.za</a>. 072 5097947

